NextPoint Therapeutics vs Pliant Therapeutics
Side-by-side comparison of AI visibility scores, market position, and capabilities
NextPoint Therapeutics is a clinical-stage immuno-oncology company targeting the HHLA2 checkpoint with two Phase 1 candidates (NPX267, NPX887); raised $122.5M total including $42.5M Series B extension co-led by Catalio in 2024.
About
NextPoint Therapeutics is a clinical-stage biotechnology company developing precision immuno-oncology therapeutics that target the HHLA2 (B7-H7) immune checkpoint pathway. HHLA2 is a novel checkpoint ligand that suppresses anti-tumor T cell and NK cell activity in many solid tumors independently of PD-L1, providing a rationale for combination with existing checkpoint inhibitors or as a monotherapy in PD-L1-resistant tumors.
Pliant Therapeutics is a clinical-stage biotech (Nasdaq: PLRX) developing integrin inhibitors for fibrotic diseases, with lead program bexotegrast in Phase 2b/3 trials for idiopathic pulmonary fibrosis.
About
Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclerosing cholangitis (PSC), and nonalcoholic steatohepatitis (NASH/MASH). Integrins are cell surface receptors that activate TGF-β, the master regulator of fibrosis — blocking specific integrin subtypes (αvβ6, αvβ1) can halt or reverse fibrosis progression without broadly suppressing immunity.
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.